Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 9/20 | 0.60 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134101 | 0.88 | ADORA1 (0.66) | ADORA1ADORA2AKMT2ACLK1RAB9A | |
| SCHEMBL6134195 | 0.87 | ADORA1 (0.49) | ADORA1ADORA2AKMT2ACLK1LMNA | |
| SCHEMBL6133391 | 0.87 | ADORA1 (0.49) | ADORA1ADORA2AKMT2ACLK1 | |
| SCHEMBL6133448 | 0.86 | ADORA1 (0.59) | ADORA1ADORA2AKMT2ARAB9A | |
| SCHEMBL6134408 | 0.85 | KMT2A (0.55) | ADORA1ADORA2AKMT2AMAOBLMNA | |
| SCHEMBL6134254 | 0.83 | MAOB (0.46) | ADORA1ADORA2AKMT2AMAOBCLK1 | |
| SCHEMBL6133571 | 0.82 | ADORA1 (0.56) | ADORA1ADORA2AKMT2ALMNARAB9A | |
| SCHEMBL6133909 | 0.82 | ADORA1 (0.62) | ADORA1ADORA2AKMT2AKDRLMNA | |
| SCHEMBL6133665 | 0.82 | ADORA1 (0.45) | ADORA1ADORA2AKMT2ARAB9A | |
| SCHEMBL6133429 | 0.81 | KMT2A (0.47) | ADORA1ADORA2AKMT2ALMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | ADORA1 3/4885ADORA2A 2/4885KMT2A 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.